Understanding the Shionogi EXPERIENCE Trials Update

01 h 01 m

An update on Shionogi’s EXPERIENCE clinical trial program in Fragile X syndrome, hosted by FRAXA and the National Fragile X Foundation. This webinar discusses the recently shared trial updates, what is known so far, and what comes next.

About the Webinar

With Dr. Michael Tranfaglia, Dr. Juan-Carlos Gomez, and Hilary Rosselot
Learn more about the presenters

A follow-up on the findings released on May 13.

About the Presenters

Juan-Carlos Gomez

Juan Carlos Gomez, MD, MBA, is the Chief Medical Officer of Shionogi, a pharmaceutical company headquartered in Osaka, Japan, that is focused on developing innovative treatments for infectious diseases and pain-CNS disorders.

Before joining Shionogi in 2019, Dr. Gomez had a long career in pharmaceutical drug development, having held senior leadership positions at Eli Lilly and Roche, mainly in neuroscience and neurodevelopmental disorders. He has a doctorate from the Universidad Complutense de Madrid and a master’s from IESE Universidad de Navarra. He is a certified specialist in psychiatry from the Hospital Clínico San Carlos in Madrid.

Hilary Rosselot

Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for several years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s in psychology, an MBA, and was previously a SOCRA-certified clinical research professional (CCRP). She enjoys spending time with her family, including her young daughter and Boston Terrier, as well as curling up with a good book.